Research Article

Additive Value of Biomarkers and Echocardiography to Stratify the Risk of Death in Heart Failure Patients with Reduced Ejection Fraction

Table 1

Clinical features of the study cohort.

VariableAll patients ()

Age (years)59 ± 12
Male gender, (%)357 (83)
Body mass index (kg/m2)27 ± 4.5
Etiology, (%)
 Ischemic164 (38)
 Nonischemic267 (62)
Comorbidities, (%)
 Hypertension120 (28)
 Diabetes81 (19)
 COPD40 (9)
New York Heart Association class, (%)
 I89 (21)
 II265 (61)
 III-IV77 (18)
Systolic blood pressure (mmHg)115 ± 18
Heart rate (beats/minutes)68 ± 12
Rhythm, (%)
 Sinus329 (77)
 Atrial fibrillation/flutter35 (8)
 Pacemaker66 (15)
 Glomerular filtration rate, MDRD (ml/min per 1.73 m2)64 ± 17
 Hgb (mg/dl)13.9 ± 1.7
 BUN (mg/dl)46 ± 19
Medications, (%)
 ACE-inhibitors/ARB340 (77)
 Beta-blockers403 (93)
 Aldosterone antagonist246 (57)
 Ivabradine11 (3)
 Digoxin52 (12)
 Furosemide (mg)74 ± 100
ICD, (%)236 (55)
CRT, (%)98 (23)

COPD: chronic obstructive pulmonary disease; Hgb: hemoglobin; BUN: blood urea nitrogen; ICD: internal cardiac defibrillator; CRT: cardiac resynchronization therapy. Values are expressed as mean ± SD or (%).